参考文献：

总论部分

［1］Bray F，Moller B.Predicting the future burden of cancer.Nat Rev Cancer，2006，6：63-74

［2］De Martel C，Ferlay J，Franceschi S，et al.Global burden of cancers attributable to infections in 2008：a reviewand synthetic analysis.Lancet Oncol，2012，13：607-615

［3］Colditz GA，Baer HJ，Tamimi RM.Cancer Epidemiology and Prevention.3rd ed.New York：Oxford UniversityPress，2006

［4］Chlebowski RT，Manson JE，Anderson GL，et al.Estrogen plus progestin and breast cancer incidence and mortality in the Women’s Health Initiative Observational Study.J Natl Cancer Inst，2013，105：526-535

［5］Edwards BK，Ward E，Kohler BA，et al.Annual report to the nation on the status of cancer，1975-2006，fea-turing colorectal cancer trends and impact of interventions（risk factors，screening，and treatment）to reduce future rates.Cancer，2010，116：544-573(https://www.daowen.com)

［6］Center MM，Jemal A，Smith RA，et al.Worldwide variations in colorectal cancer.CA Cancer J Clin，2009，59：366-378

［7］Jha P.Avoidable global cancer deaths and total deaths from smoking.Nat Rev Cancer，2009，9：655-664

［8］Stellman SD，Wang QS.Cancer Mortality in Chinese Immigrants to New York.Cancer，1994，73：1270-1275

［9］Driscoll T，Nelson DI，Steenland K，et al.The global burden of diseases due to occupational carcinogens.Am JInd Med，2005，48（6）：419-431

［10］Zitvogel L，Apetoh L，Ghiringhelli F，et al.Immunological aspects of cancer chemotherapy.Nat Rev Immunol，2008，8（1）：59-73

［11］Marigo I，Dolcetti L，Zanovello P，et al.Tumor-induced tolerance and jm.Mune suppression by myeloid derived suppressor cells.Immunol rev，2008，222（1）：162-179